XML 79 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Geographic and Segment Information Segment Info (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
geographic_region
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
geographic_region
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting Information [Line Items]          
Reportable segments | segment     2    
Number of geographic regions in which entity operates | geographic_region 3   3    
Net sales $ 240,083 $ 268,610 $ 664,686 $ 796,580  
Merger and integration expenses 1,094 6,716 6,616 14,345  
Restructuring expenses (349) 698 2,025 4,563  
Amortization of intangibles 9,685 11,146 29,346 29,690  
Operating (loss) income from continuing operations (7,508) 25,761 (22,137) (24,894)  
Interest income 47 151 482 624  
Interest expense (14,673) (4,774) (25,237) (10,490)  
Foreign exchange and other gains (losses) 3,420 327 507 (795)  
(Loss) income from continuing operations before tax (18,714) 21,465 (46,385) (35,555)  
Assets 2,521,748   2,521,748   $ 2,411,797
Operating Segments | Cardiovascular          
Segment Reporting Information [Line Items]          
Net sales 140,878 155,426 417,482 483,161  
Restructuring expenses 9 783 1,265 1,521  
Operating Segments | Neuromodulation          
Segment Reporting Information [Line Items]          
Net sales 98,408 112,543 245,277 311,461  
Restructuring expenses 43 (171) 851 314  
Other          
Segment Reporting Information [Line Items]          
Net sales 797 641 1,927 1,958  
Restructuring expenses (401) 86 (91) 2,728  
Continuing Operations          
Segment Reporting Information [Line Items]          
Total reportable segment income from continuing operations 2,922 44,321 15,850 23,704  
Merger and integration expenses 1,094 6,716 6,616 14,345  
Restructuring expenses (349) 698 2,025 4,563  
Amortization of intangibles 9,685 11,146 29,346 29,690  
Operating (loss) income from continuing operations (7,508) 25,761 (22,137) (24,894)  
Capital expenditures 9,217 6,005 28,236 16,801  
Continuing Operations | Operating Segments | Cardiovascular          
Segment Reporting Information [Line Items]          
Total reportable segment income from continuing operations (7,311) 36,180 (8,037) 47,289  
Assets 1,463,523   1,463,523   1,546,520
Capital expenditures 7,040 5,178 17,777 13,564  
Continuing Operations | Operating Segments | Neuromodulation          
Segment Reporting Information [Line Items]          
Total reportable segment income from continuing operations 21,154 30,010 82,294 52,260  
Assets 668,899   668,899   749,069
Capital expenditures 1,210 136 7,285 666  
Continuing Operations | Other          
Segment Reporting Information [Line Items]          
Total reportable segment income from continuing operations (10,921) (21,869) (58,407) (75,845)  
Assets 389,326   389,326   $ 116,208
Capital expenditures 967 691 3,174 2,571  
United States          
Segment Reporting Information [Line Items]          
Net sales 128,863 138,426 330,633 401,400  
United States | Operating Segments | Cardiovascular          
Segment Reporting Information [Line Items]          
Net sales 49,009 49,993 133,288 155,530  
United States | Operating Segments | Neuromodulation          
Segment Reporting Information [Line Items]          
Net sales 79,854 88,433 197,345 245,870  
Europe          
Segment Reporting Information [Line Items]          
Net sales 48,529 50,235 138,606 165,267  
Europe | Operating Segments | Cardiovascular          
Segment Reporting Information [Line Items]          
Net sales 38,054 39,810 111,132 131,187  
Europe | Operating Segments | Neuromodulation          
Segment Reporting Information [Line Items]          
Net sales 10,475 10,425 27,474 34,080  
Rest of World          
Segment Reporting Information [Line Items]          
Net sales 62,691 79,949 195,447 229,913  
Rest of World | Operating Segments | Cardiovascular          
Segment Reporting Information [Line Items]          
Net sales 53,815 65,623 173,062 196,444  
Rest of World | Operating Segments | Neuromodulation          
Segment Reporting Information [Line Items]          
Net sales 8,079 13,685 20,458 31,511  
Cardiopulmonary          
Segment Reporting Information [Line Items]          
Net sales 107,200 120,014 324,623 372,163  
Cardiopulmonary | United States          
Segment Reporting Information [Line Items]          
Net sales 33,549 39,054 96,223 119,580  
Cardiopulmonary | Europe          
Segment Reporting Information [Line Items]          
Net sales 29,947 30,052 87,475 99,933  
Cardiopulmonary | Rest of World          
Segment Reporting Information [Line Items]          
Net sales 43,704 50,908 140,925 152,650  
Heart Valves          
Segment Reporting Information [Line Items]          
Net sales 21,136 28,877 63,813 87,901  
Heart Valves | United States          
Segment Reporting Information [Line Items]          
Net sales 3,129 4,626 8,990 13,660  
Heart Valves | Europe          
Segment Reporting Information [Line Items]          
Net sales 7,945 9,572 22,822 30,757  
Heart Valves | Rest of World          
Segment Reporting Information [Line Items]          
Net sales 10,062 14,679 32,001 43,484  
Advanced Circulatory Support          
Segment Reporting Information [Line Items]          
Net sales 12,542 6,535 29,046 23,097  
Advanced Circulatory Support | United States          
Segment Reporting Information [Line Items]          
Net sales 12,331 6,313 28,075 22,290  
Advanced Circulatory Support | Europe          
Segment Reporting Information [Line Items]          
Net sales 162 186 835 497  
Advanced Circulatory Support | Rest of World          
Segment Reporting Information [Line Items]          
Net sales $ 49 $ 36 $ 136 $ 310